Oramed Pharmaceuticals Inc. (ORMP)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 3 | 3 | 3 | 1 | 0 | 2 | - | 1 |
| Operating profit | $m | -15 | - | ||||||
| Net profit | $m | -12 | -22 | -38 | 6 | -19 | 64 | - | 190 |
| EPS reported | $ | 1.50 | - | ||||||
| Operating cashflow per share | $ | -0.22 | - | ||||||
| Capex per share | $ | 0.05 | - | ||||||
| FCF per share | $ | -0.27 | - | ||||||
| Free cash flow | $m | -11 | - | ||||||
| Net debt | $m | -126 | - | ||||||
| Book value equity | $m | 200 | - | ||||||
| Book value per share | $ | 4.71 | - | ||||||
| Number of shares | m | 42.42 | - | ||||||
| DPS (TTM paid) | $ | 0.25 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 1.90 | - | ||||||
| P/B LTM | x | 0.59 | - | ||||||
| P/S LTM | x | 59.00 | - | ||||||
| P/FCF LTM | x | -10.65 | - | ||||||
| EV/EBITDA LTM | x | 0.97 | - | ||||||
| EV/Sales LTM | x | 36.44 | - | ||||||
| Earnings Yield LTM | % | +52.63% | - | ||||||
| FCF Yield | % | -9.39% | - | ||||||
| Quality | |||||||||
| ROE | % | +32.07% | - | ||||||
| ROIC | % | -6.05% | - | ||||||
| Operating margin | % | -7.54% | - | ||||||
| Gross margin | % | +0.65% | - | ||||||
| FCF/Sales | % | -553.90% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -13.43 | - | ||||||
| Net Debt/EBITDA | x | -0.60 | - | ||||||
| EBIT/Net interest | x | 0.00 | - | ||||||
| Net debt/market cap | % | +0.24% | - | ||||||
| Net debt/Equity | x | -0.63 | - | ||||||
| Gross debt/equity | x | 0.00 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Oramed Pharmaceuticals Inc. (ORMP)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free